COX-2 as a molecular target of colon cancer chemoprevention: Promise and reality

Biomedicine and Aging Pathology

Volumn 2, Issue 3, 2012, Pages 67-72

  Kaur, Jasmeet ^a   Vaish, Vivek ^b   Sanyal, Sankar Nath ^b  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PANJAB UNIVERSITY   (India)

Author keywords

Chemoprevention; Colon cancer; COX 2; Coxibs; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; ICOSANOID; LIPOXYGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN; ROFECOXIB; SULINDAC; TRASTUZUMAB;

ADENOMATOUS POLYP; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; FAMILIAL ADENOMATOUS POLYP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MACROPHAGE; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84867332640     PISSN: 22105220     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomag.2012.07.007     Document Type: Review

References (76)

1. G. Kune, S. Kune, and L. Watson Colorectal cancer risk, chronic illnesses, operations and medications: case-control results from the Melbourne Colorectal Cancer Study Cancer Res 48 1988 4399 4404
2. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues J Natl Cancer Inst 94 2002 252 266
3. J.A. Baron, B.F. Cole, R.S. Sandler, R.W. Haile, D. Ahnen, and R. Bresalier A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891 899
4. R.S. Sandler, S. Halabi, J.A. Baron, S. Budinger, E. Paskett, and R. Keresztes A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 2003 883 890
5. J. Vane Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs Nat New Biol 231 1971 232 235
6. D. Dewitt, and W.L. Smith Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence Proc Natl Acad Sci U S A 85 1988 1412 1416
7. J. Merlie, D. Fagan, J. Mudd, and P. Needleman Isolation and characterization of the complimentary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase) J Biol Chem 263 1988 3550 3553
8. C. Yokoyama, T. Takai, and T. Tanabe Primary structure of sheep seminal vesicle prostaglandin endoperoxide synthase deduced from cDNA sequence FEBS Lett 231 1988 347 351
9. J. Vane, Y. Bakhle, and R. Botting Cyclooxygenase 1 and 2 Annu Rev Pharmacol Toxicol 38 1998 97 120
10. C. Luong, A. Miller, J. Barnett, J. Chow, C. Ramesha, and M.F. Browner Flexibility of the NSAID binding site in the structure of human cyclo-oxygenase-2 Nat Struct Biol 11 1996 927 933
11. T. Smith Cyclooxygenases as the principle targets for the action of NSAID's Rheum Dis Clin North Am 24 1998 501 523
12. D. Dewitt Prostaglandin endoperoxide synthase: regulation of enzyme expression Biochim Biophys Acta 1083 1991 121 134
13. J. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, and J.R. Vane Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc Natl Acad Sci U S A 90 1993 11693 11697
14. J. Schwartz, C. Chan, S. Mukhopadhyay, K.J. McBride, T.M. Jones, and S. Adcock Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans Clin Pharmacol Ther 65 1999 653 660
15. R. Soslow, A. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, and J. Masferrer COX-2 is expressed in human pulmonary, colonic and mammary tumors Cancer 89 2000 2637 2645
16. E. Meade, W. Smith, and D. deWitt Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs J Biol Chem 268 1993 6610 6614
17. W. Smith, and D. Dewitt Prostaglandin endoperoxide H synthases-1 and -2 Adv Immunol 62 1996 167 215
18. D. DeWitt COX-2 selective inhibitors: the new super aspirins Mol Pharmacol 55 1999 625 631
19. S. Kargman, S. Charleson, M. Cartwright, J. Frank, D. Riendeau, and J. Mancini Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts Gastroenterology 111 1996 445 454
20. C. Eberhart, R. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
21. W. Smalley, W. Ray, J. Daugherty, and M.R. Griffin Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study Arch Intern Med 159 1999 161 166
22. F. Giardiello, S. Hamilton, A. Krush, S. Piantadosi, L.M. Hylind, and P. Celano Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis N Engl J Med 328 1993 1313 1316
23. H. Sheng, J. Shao, S. Kirkland, P. Isakson, R.J. Coffey, and J. Morrow Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 J Clin Invest 99 1997 2254 2259
24. T. Kawamori, C. Rao, K. Seibert, and B. Reddy Chemoprotective activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis Cancer Res 58 1998 409 412
25. M. Oshima, J. Dinchuk, S. Kargman, H. Oshima, B. Hancock, and E. Kwong Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
26. G. Steinbach, P. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, and G.B. Gordon The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
27. A. Nobuoka, T. Takayama, K. Miyanishi, T. Sato, K. Takanashi, and T. Hayashi Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid Gastroenterology 127 2004 428 443
28. P.C. Chulada, M.B. Thompson, J.F. Mahler, C.M. Doyle, B.W. Gaul, and C. Lee Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res 60 2000 4705 4708
29. J. Kaur, and S.N. Sanyal Association of PI3-kinase and Wnt signaling in non-steroidal anti-inflammatory drug-induced apoptosis in experimental colon cancer Am J Biomed Sci 1 2009 395 405
30. J. Kaur, and S.N. Sanyal Induction of apoptosis as potential chemopreventive effect of dual cyclooxygenase inhibitor, diclofenac in early colon carcinogenesis J Environ Pathol Toxicol Oncol 29 2010 41 53
31. L. Tanwar, V. Vaish, and S.N. Sanyal Chemoprevention of 1,2-dimethylhydrazine-induced colon carcinogenesis by a non-steroidal anti-inflammatory drug, etoricoxib, in rats: inhibition of nuclear factor kappaB Asian Pac J Cancer Prev 10 2009 1141 1146
32. L. Tanwar, V. Vaish, and S.N. Sanyal Chemopreventive role of etoricoxib (MK-0663) in experimental colon cancer: induction of mitochondrial proapoptotic factors Eur J Cancer Prev 19 2010 280 287
33. V. Vaish, L. Tanwar, and S.N. Sanyal The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors Tumour Biol 31 2010 427 436
34. V. Vaish, L. Tanwar, J. Kaur, and S.N. Sanyal Chemopreventive effects of non-steroidal anti-inflammatory drugs in early neoplasm of experimental colorectal cancer: an apoptosome study J Gastrointest Cancer 42 2011 195 203
35. V. Vaish, and S.N. Sanyal Non-steroidal anti-inflammatory drugs modulate the physicochemical properties of plasma membrane in experimental colorectal cancer: a fluorescence spectroscopic study Mol Cell Biochem 358 2011 161 171
36. S. Singh Kanwar, V. Vaish, and S. Nath Sanyal Altered membrane lipid dynamics and chemoprevention by non-steroidal anti inflammatory drugs during colon carcinogenesis Nutr Hosp 26 2011 1141 1154
37. V. Vaish, and S.N. Sanyal Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer Pharmacol Rep 63 2011 1210 1221
38. V. Vaish, and S.N. Sanyal Role of Sulindac and Celecoxib in chemoprevention of colorectal cancer via intrinsic pathway of apoptosis: Exploring NHE-1, intracellular calcium homeostasis and Calpain 9 Biomed Pharmacother 66 2012 116 130
39. V. Vaish, and S.N. Sanyal Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling Biomed Pharmacother 66 2012 354 367
40. H. Piplani, V. Vaish, and S.N. Sanyal Dolastatin 15, a mollusk linear peptide and Celecoxib, a selective cyclooxygenase-2 inhibitor prevent preneoplastic colonic lesions and induce apoptosis via inhibition of the regulatory transcription factor, NF-κB and an inflammatory protein, iNOS Eur J Cancer Prev 2012 10.1097/CEJ.0b013e328351c69d
41. H. Takeda, M. Sonoshita, H. Oshima, K. Sugihara, P.C. Chulada, and R. Langenbach Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis Cancer Res 63 2003 4872 4877
42. C.T. Dang, A.J. Dannenberg, K. Subbaramaiah, M.N. Dickler, and M.M. Moasser Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments Clin Cancer Res 10 2004 4062 4067
43. T. Higuchi, T. Iwama, K. Yoshinaga, M. Toyooka, M.M. Taketo, and K. Sugihara A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients Clin Cancer Res 9 2003 4756 4760
44. C.R. Becerra, E.P. Frenkel, R. Ashfaq, and R.B. Gaynor Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study Int J Cancer 105 2003 868 872
45. A.J. Dannenberg, and K. Subbaramaiah Targeting cyclooxygenase-2 in human neoplasia: rationale and promise Cancer Cell 4 2003 431 436
46. T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, and J.R. Vane Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis Proc Natl Acad Sci U S A 96 1999 7563 7568
47. F.M. Giardiello, S.R. Hamilton, A.J. Krush, S. Piantadosi, L.M. Hylind, and P. Celano Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis N Engl J Med 328 1993 1313 1316
48. G. Winde, K.W. Schmid, W. Schlegel, R. Fischer, H. Osswald, and H. Bunte Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months Dis Colon Rectum 38 1995 813 830
49. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Longterm Arthritis Safety Study J Am Med Assoc 284 2000 1247 1255
50. G.A. Fitzgerald Coxibs and cardiovascular disease N Engl J Med 351 2004 1709 1711
51. D.L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 2004 387 437
52. J.N. Topper, J. Cai, D. Falb, and M.A. Gimbrone Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress Proc Natl Acad Sci U S A 93 1996 10417 10422
53. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, and G.A. Fitzgerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci U S A 96 1999 272 277
54. R.L. Keith, Y.E. Miller, Y. Hoshikawa, M.D. Moore, T.L. Gesell, and B. Gao Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer Cancer Res 62 2002 734 740
55. R.L. Keith, Y.E. Miller, T.M. Hudish, C.E. Girod, S. Sotto-Santiago, and W.A. Franklin Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice Cancer Res 64 2004 5897 5904
56. I. Shureiqi, and S.M. Lippman Lipoxygenase modulation to reverse carcinogenesis Cancer Res 61 2001 6307 6312
57. J.T. Mao, I.H. Tsu, S.M. Dubinett, B. Adams, T. Sarafian, and F. Baratelli Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide Clin Cancer Res 10 2004 6872 6878
58. R. Hanif, A. Pittas, Y. Feng, M.I. Koutsos, L. Qiao, and L. Staiano-Coico Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway Biochem Pharmacol 52 1996 237 245
59. S.J. Shiff, and B. Rigas The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs) J Exp Med 190 1999 445 450
60. J.L. Williams, N. Nath, J. Chen, T.R. Hundley, J. Gao, and L. Kopelovich Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB and NO synthase 2 inhibition: implications for chemoprevention Cancer Res 63 2003 7613 7618
61. J. Marx Cancer research. Anti-inflammatories inhibit cancer growth-but how? Science 291 2001 581 582
62. S.J. Shiff, L. Qiao, L.L. Tsai, and B. Rigas Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells J Clin Invest 96 1995 491 503
63. S. Grosch, I. Tegeder, E. Niederberger, L. Brautigam, and G. Geisslinger COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib FASEB J 15 2001 2742 2744
64. J. Kaur, and S.N. Sanyal Intrinsic mitochondrial membrane potential change and associated events mediate apoptosis in chemopreventive effect of diclofenac in colon cancer Oncol Res 18 2010 481 492
65. J. Kaur, and S.N. Sanyal PI3-kinase/Wnt signaling association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis and its chemoprevention by diclofenac Tumor Biol 31 2010 623 631
66. J. Kaur, and S.N. Sanyal Oxidative stress and stress-signaling in chemoprevention of early colon cancer by diclofenac Am J Biomed Sci 2 2010 63 78
67. J. Kaur, and S.N. Sanyal Modulation of inflammatory changes in early stages of colon cancer through activation of PPARγ by diclofenac Eur J Cancer Prev 19 2010 319 327
68. A.F. Badawi, M.B. Eldeen, Y. Liu, E.A. Ross, and M.Z. Badr Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma Cancer Res 64 2004 1181 1189
69. H. Ding, C. Han, J. Zhu, C.S. Chen, and S.M. D'Ambrosio Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9 Int J Cancer 113 2005 803 810
70. T.J. Maier, K. Schilling, R. Schmidt, G. Geisslinger, and S. Grosch Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells Biochem Pharmacol 67 2004 1469 1478
71. S.H. Teh, A.K. Hill, D.A. Foley, E.W. McDermott, N.J. O'Higgins, and L.S. Young COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells J Cell Biochem 91 2004 796 807
72. Y. Sun, X.M. Tang, E. Half, M.T. Kuo, and F.A. Sinicrope Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells Cancer Res 62 2002 6323 6328
73. A. Weber, A. Casini, A. Heine, D. Kuhn, C.T. Supuran, and A. Scozzafava Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition J Med Chem 47 2004 550 557
74. K. Yamaguchi, S.H. Lee, T.E. Eling, and S.J. Baek Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway J Biol Chem 279 2004 49617 49623
75. C. Waskewich, R.D. Blumenthal, H. Li, R. Stein, D.M. Goldenberg, and J. Burton Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines Cancer Res 62 2002 2029 2033
76. G. Eibl, Y. Takata, L.G. Boros, J. Liu, Y. Okada, and H.A. Reber Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor Cancer Res 65 2005 982 990